Patents by Inventor Pere Puigserver

Pere Puigserver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11247970
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating and/or preventing a metabolic condition, such as diabetes.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: February 15, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute, The Broad Institute, Inc.
    Inventors: Pere Puigserver, Kfir Sharabi, Theodore Kamenecka, Patrick Griffin, Stuart L. Schreiber, Roger Schilling, Partha P. Nag, Joshua A. Bittker
  • Publication number: 20200317620
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating and/or preventing a metabolic condition, such as diabetes.
    Type: Application
    Filed: March 21, 2018
    Publication date: October 8, 2020
    Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute
    Inventors: Pere PUIGSERVER, Kfir SHARABI, Theodore KAMENECKA, Patrick GRIFFIN, Stuart L. SCHREIBER, Roger SCHILLING, Partha P. NAG, Joshua A. BITTKER
  • Publication number: 20090098569
    Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 20, 2007
    Publication date: April 16, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
  • Publication number: 20070248590
    Abstract: Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: December 1, 2006
    Publication date: October 25, 2007
    Applicant: Sirtris Pharmaceuticals, Inc.
    Inventors: Jill Milne, Karl Normington, Pere Puigserver, Joseph Rodgers
  • Patent number: 7250283
    Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: July 31, 2007
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
  • Patent number: 6908987
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: June 21, 2005
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6872391
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 29, 2005
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Publication number: 20040254362
    Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 20, 2004
    Publication date: December 16, 2004
    Inventors: Bruce M Spiegelman, Guillaume Adelmant, Pere Puigserver
  • Publication number: 20030229204
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 16, 2003
    Publication date: December 11, 2003
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Publication number: 20030073819
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 17, 2003
    Applicant: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6525178
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6426411
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: July 30, 2002
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Publication number: 20020082413
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 5, 2001
    Publication date: June 27, 2002
    Applicant: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6166192
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: December 26, 2000
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu